Tetris Pharma Ltd.

Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND MEDTRONIC DIABETES ESTABLISH COLLABORATION TO DEVELOP A NOVEL THERMOSTABLE INSULIN FOR IMPLANTABLE PUMP DELIVERY Medtronic to fund Arecor’s development of Arestat™ enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination with a next-generation implantable pump Cambridge, UK, 9 May 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announced a research collaboration with Medtronic plc (NYSE: MDT), a global leader in healthcare technology, to develop a novel, high concentration, thermostable insulin for use by Medtronic’s Diabetes business in a next-generation implantable pump. This new insulin has the potential to bring significant advancements in the current insulin treatment options for a small population of patients who have limited options for controlling their diabetes with traditional therapy. This collaboration has the potential to allow for the continued care of these patients with an insulin that may minimise the need for pump maintenance interventions and expand the utility for physicians, whilst saving healthcare costs. Sarah Howell, Chief Executive Officer of Arecor, said: “Our leadership in this field has been demonstrated through our best-in-class ultra-rapid acting clinical development programmes (AT278 & AT247). Within the diabetes field more broadly we are seeing the rise of innovative delivery devices, including longer-wear and miniaturised pumps that are continually improving treatment options for patients. We are excited to play our part in this progress with the development of a highly differentiated insulin with the potential to transform treatment for an extremely vulnerable patient group. This collaboration is one of many we hope to enable, to further enhance the benefits of these next-generation devices.” Gary Dulak, Senior Director, New Venture Programs Medtronic Diabetes, said: “Medtronic Diabetes is a pioneer in implantable insulin pump systems for people living with type 1 diabetes, who are unable to tolerate conventional therapy that delivers insulin subcutaneously (under the skin). With intraperitoneal therapy via an implantable insulin pump system, insulin delivery is targeted for direct absorption by the liver via the implantable pump. We are pleased to collaborate with Arecor to explore new ways to develop this critical therapeutic option for the subset of individuals who may benefit from it.” This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 (“UK MAR”). Product not approved by the FDA for any use and not available for research or commercial use in the US. -ENDS- For more information, please contact: Arecor Therapeutics plcwww.arecor.comDr Sarah Howell, Chief Executive OfficerTel: +44 (0) 1223 426060Email: info@arecor.com Susan Lowther, Chief Financial OfficerTel: +44 (0) 1223 426060Email: info@arecor.com Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance)Rupert Dearden (Corporate Broking)Tel: +44 (0) 20 7886 2500 WG Partners LLP (Financial Advisor) Nigel Barnes, Satheesh NadarajahDavid Wilson, Claes SpangTel: +44 (0)203 705 9321 ICR Consilium Chris Gardner, David Daley, Lindsey NevilleTel: +44 (0) 20 3709 5700Email: arecor@consilium-comms.com Notes to Editors About Arecor Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. The collaboration adds to Arecor’s broad programme of diabetes focused activities, led by its two lead proprietary clinical development programmes – AT278 and AT247, two ultra-rapid acting insulin candidates that offer the potential to simplify and improve blood glucose control for people living with diabetes and could enable the development of next- generation miniaturised insulin delivery systems and a fully closed loop artificial pancreas system. In March 2024, Arecor established a research collaboration with TRx Biosciences for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product that would provide a more convenient treatment option for patients with diabetes and obesity. The Group’s specialty pharmaceutical business, Tetris Pharma, commercialises Ogluo®, a glucagon prefilled autoinjector pen for patients living with diabetes suffering from severe hypoglycaemia. For further details please see our website, www.arecor.com

Classic G FUEL Flavors Remastered and Resized to Celebrate New Era of Neopets NEW YORK, Aug. 11, 2023 /PRNewswire/ -- G FUEL celebrates a fantastic new era of the virtual pet game Neopets with a limited-edition collection featuring remastered G FUEL Energy Formula products, a Neopets x G FUEL Slushie Cup and collectible G FUEL Doodlez Charms accessories. The collaboration, which debuted at San Diego Comic-Con International 2023, features three fan-favorite flavors with adorable Neopets characters on the packaging, available for the first time in 15-serving tubs: Continue Reading G FUEL's Neopets Collection is now available at GFUEL.com! Electric Blue Slushie (Snow Cone) Cheops Slushie (Cherry Pomegranate/Clickbait) Loveberry Slushie (Raspberry Lemonade/Hype Sauce) Neopets and G FUEL fans alike can enjoy each of these flavors in the limited-edition Neopets x G FUEL Slushie Cup, which can be customized with one of three exclusive Neopets Doodlez Charms, featuring some of the most iconic Neopets: Kougra, Shoyru, and Aisha. "Like a magical potion brewed in one of the many lands of Neopia, this collaboration infuses the power of play with the energy to excel. We are so thrilled to partner Neopets with G FUEL," said Colleen Gilday, SVP at CWA, licensing agent for Neopets. G FUEL Energy Formula is zero sugar and loaded with antioxidants from 18 different fruit extracts. Each serving has only 15 calories and contains 140 mg of caffeine. Electric Blue Slushie, Cheops Slushie and Loveberry Slushie will help keep Neopets fans focused and energized as they explore the wonders of Neopia, whether through the upcoming World of Neopets mobile game or on the classic website that started it all, Neopets.com. "Our fans are incredibly passionate and energetic when it comes to adventuring through the wide range of Neopian experiences. The opportunity to nourish that energy and passion for adventure with this amazing collaboration made a G FUEL partnership an easy decision," said Dominic Law, CEO of Neopets. Whether helping players grind 80+ newly relaunched classic games, dominate in the Battledome, or dive into the lore of all of their favorite Neopian characters on the brand new Neopets homepage, G FUEL powers players with the clear, focused energy they need to rake in the Neopoints. "Neopets has always existed at the intersection of gaming and community – just like G FUEL – so we're proud to be part of this immersive new era for the brand," said G FUEL Founder and CEO Cliff Morgan. "Plus, Neopets is all about cuteness, so we were able to shrink down three of our fan-favorite 40-serving tubs into 15-serving Neopets mini tubs that are the perfect combination of adorable and energizing." Neopians everywhere can make like a Kougra and pounce on G FUEL's limited-edition Neopets collection. Available now at GFUEL.com while supplies last! About Neopets Neopets is an immersive, online virtual pet game in which players can adopt, customize, and interact with Neopets in the vast world of Neopia. Known for its multi-generational, passionate community, Neopets offers players a vast world of storytelling, collecting, pet care, and exciting social gaming experiences. Since its launch in 1999, Neopets has galvanized unique adventures, games, stories, and challenges for over 150 million players worldwide. Follow us at: Facebook: @Neopets Instagram: @NeopetsOfficialAccount Twitter: @Neopets TikTok: @OfficialNeopets About Carlin West Agency CWA (Carlin West Agency LLC.) is a leading brand building and merchandise licensing company representing licensing rights to children's/pop culture entertainment brands such as Neopets, global pop star Hatsune Miku, Winx Club, Pet Rock and others. CWA is based in New York City. For more information, please visit . About G FUEL G FUEL provides fans with a game-changing, performance-driven alternative to standard energy drink products. With an ever-expanding, sugar-free product lineup that includes a powdered Energy Formula, ready-to-drink cans, powdered Hydration Formula and Protein Puffs snacks, G FUEL has firmly established itself as a market leader in the energy drink industry.   With more than 346,000 5-star Shopper Approved Ratings, a shipping network that spans over 125 countries, a nationwide retail campaign, and a global social media footprint of over 1 billion followers, G FUEL maintains the industry's largest and most passionate community of fans, customers, content creators, and partners. Content creators and partners include the likes of Ninja, NoisyButters, PewDiePie, Mikal Bridges, Michael Dickson, Activision, SEGA of America, Capcom®, EA, Bethesda Game Studios, Warner Bros., VIZ Media, Rare Ltd., Disney, Lucasfilm, Sony Pictures, The Tetris Company and Bandai Namco Entertainment Inc. Join the movement today at GFUEL.com and follow us on social media @GFuelEnergy.  Press Contact: [email protected] Distribution and Wholesale Contact: [email protected] SOURCE G FUEL

Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Strong pipeline of revenue-generating collaborations with major pharmaceutical and biotech companies with further deals anticipated during H2 and beyondSignificant progress across proprietary diabetes focused portfolio with AT278 scheduled to complete within Q4 2023Good partner progress across licensed portfolio Cambridge, UK, 20 July 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today provides a business update and announces that its interim results for the six months ended 30 June 2023 will be issued in mid-September. Arecor is pleased to report strong progress across the business in the first half of 2023, with advances across its in-house and partnered programmes and continued success in the roll-out of Ogluo® in key territories. Arecor looks forward to providing a full update on performance and outlook at the time of its interim results. The Group's unaudited cash position at 30 June 2023 was £8.2 million. Sarah Howell, Chief Executive Officer at Arecor, said: “We have continued to make significant progress across all areas of the business, strengthening the foundations for future growth across our in-house proprietary products and partnered programmes and supported by a revenue contribution from our commercial subsidiary, Tetris Pharma. Later this year we expect key data for AT278 and anticipate further value inflection points within our licensed product portfolio. With further partnerships and collaborations expected, we are continuing towards our ambition of building a significant self-sustaining biopharmaceutical company.” The Group has continued to make strong progress across its proprietary diabetes focused portfolio. The second Phase I clinical trial of AT278 in Type 2 diabetic patients is scheduled to complete within Q4 2023. AT278 is an ultra-rapid, ultra-concentrated (500U/mL) insulin candidate that has been designed to accelerate the absorption of insulin post injection, despite a 5-fold increase in concentration compared with 100U/mL insulins available to patients today. It has the potential to become the gold standard treatment for the growing population of people with diabetes with high daily insulin needs as the first and potentially only concentrated, yet rapid acting insulin. A truly rapid acting, concentrated insulin is also a critical step towards the advancement of the next generation of longer wear and miniaturised insulin delivery devices. Positive results from the Group’s second Phase I clinical trial investigating ultra-rapid acting insulin product candidate, AT247, presented at the American Diabetes Association (ADA) 83rd Scientific Sessions meeting in June 2023, clearly demonstrate faster insulin absorption than current, gold-standard, rapid acting insulins and reinforce AT247’s potential to enable a fully closed loop artificial pancreas – a life changing treatment approach for people living with diabetes. The Group maintains a strong pipeline of revenue-generating collaborations with major pharmaceutical and biotech companies with further deals anticipated in H2 and beyond. In June 2023, the Group entered into a revenue-generating agreement with a leading biopharmaceutical company to support development of a biosimilar product. This collaboration follows an earlier technology partnership between the two companies, further demonstrating the strength and relevance of the Group’s technology platform and expertise. This was the second agreement signed in the first half of 2023, after an additional formulation agreement with an existing Top 5 pharma partner in February, bringing the total number of new technology partnerships signed to 10 since IPO. These partnerships deliver revenue and offer significant upside potential from licensing under milestone and royalty bearing agreements. The Group’s three licensed programmes, under milestone and royalty-based agreements or equivalent, have also advanced. Arecor continues to expect the first product incorporating its Arestat™ technology, AT220, to be commercialised by its partner under a royalty-generating license agreement in a multi-billion dollar market, with US FDA approval anticipated in H2 2023. In addition, Hikma continues to progress AT307, a ready-to-use ("RTU") injectable medicine after its milestone-triggering transfer from Arecor in January 2023. The Group was also pleased to note, in April 2023, that its partner Inhibrx initiated a registration-enabling trial of INBRX-101, an Arestat™ formulated optimized recombinant human AAT-Fc fusion protein, for treatment of patients with emphysema due to alpha-1 antitrypsin deficiency (AATD). Tetris Pharma, the speciality pharmaceutical company acquired by Arecor in August 2022, continues the European commercial roll out of its key diabetes product, Ogluo® (glucagon prefilled autoinjector pen), adding Denmark and Norway in May 2023, to existing markets in Austria, Germany and the UK, and sales continue to grow. During the remainder of H2 2023, Tetris Pharma will focus on accelerating market adoption of Ogluo® and roll-out across key territories. With this continued focus on growing and maximising the value of Ogluo® in the UK and Europe, Dr Shafiq Choudhary, Founder and Managing Director, will be leaving the business later this year following a handover period. The Management Team and Board of Arecor thank Shafiq for his contribution and commitment since the acquisition. The momentum we are seeing and the increasingly pan-European focus of our commercial efforts provide the Group with continued confidence in Ogluo®. Sales of Gvoke® in the US also remain strong with continued quarter on quarter growth and, while the market dynamics clearly differ, the US experience provides further support for the Group’s belief in the growth potential of the product in the UK and Europe. The Group has continued to strengthen its patent portfolio to protect its Arestat™ technology platform and proprietary pipeline products, with six new patent grants this year, most recently, in June 2023, announcing key patents from the European Patent Office and the China National Intellectual Property Administration, protecting novel formulations of AT278 and AT247. The Group's intellectual property (IP) portfolio currently comprises 36 patent families, including >75 granted patents in Europe, the US and in other key territories. This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"). -ENDS- For more information, please contact: Arecor Therapeutics plcwww.arecor.comDr Sarah Howell, Chief Executive OfficerTel: +44 (0) 1223 426060Email: info@arecor.com Susan Lowther, Chief Financial OfficerTel: +44 (0) 1223 426060Email: info@arecor.com Mo Noonan, CommunicationsTel: +44 (0) 7876 444977Email: mo.noonan@arecor.com Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance)Rupert Dearden (Corporate Broking)Tel: +44 (0) 20 7886 2500 Consilium Strategic Communications Chris Gardner, David Daley, Lindsey NevilleTel: +44 (0) 20 3709 5700Email: arecor@consilium-comms.com Notes to EditorsAbout Arecor Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com